Valeant (VRX) Could Take a Large Write Down on Sprout - Wells Fargo's Maris
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Wells Fargo analyst David Maris sees Valeant Pharmaceuticals (NYSE: VRX) taking a large impairment charge on the carrying value of Sprout.
The charge could be as much 90% of its value, or more, Maris said, and without the addback to adjusted earnings going forward, this write-off would be a $0.14 per share headwind to annual adjusted EPS in 2017E and beyond.
"We believe there may be other assets that face this same problem, compounding Valeant’s divestiture plans, as Valeant would lose not only the cash flow from the products, but the addback to adjusted EPS of potentially overstated intangible asset amortization," he added.
The firm maintained their Underperform rating and $17-$22 valuation range.
Shares of Valeant Pharmaceuticals closed at $26.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades Essex Property Trust (ESS) to Overweight
- Expect Facebook (FB) To Show Strong Q4 Report, Monitor For Guidance On Expenses - Goldman Sachs
- Herbalife's (HLF) Debt Package News Seen as 'Enormous Positive' at Pivotal Research
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Hot Comments, Short Sales, Trader Talk
Related EntitiesEarnings, Wells Fargo, David Maris
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!